A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Beta lapachone (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors KT&G Life Sciences
- 31 Mar 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record
- 14 Jan 2014 New trial record